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Abstract
Background
It is widely reported that long-term use of four preventive medications (antiplatelet agents,
angiotensin converting enzyme inhibitor / angiotensin receptor blocker, statin and beta-
blockers) reduce the risk of subsequent acute coronary syndromes (ACS). It is unclear
whether these four medications benefit patients who develop ACS despite its use.
Methods and Results
Logistic regression and propensity-score was applied among 14790 ACS patients to assess
the association between prior use of four preventive medications and in-hospital outcomes
including severity of disease at presentation (type of ACS, systolic blood pressure <90
mmHg, and heart rate> = 100 beats/min), complicating arrhythmia and major adverse car-
diovascular events (MACEs, including all deaths, non-fatal myocardial infarction or re-
infarction, and non-fatal stroke). Prior use of each of the four medications was significantly
associated with less severity of disease (ORs ranged from 0.40 to 0.82, all P<0.05), less
arrhythmia (ORs ranged from 0.45 to 0.64, all P<0.05), and reduced risk of MACEs (ORs
ranged from 0.59 to 0.73, all P<0.05) during hospitalization. Multiple variable-adjusted ORs
of MACEs were 0.77, 0.67, 0.48 and 0.59 respectively in patients with 1, 2, 3 and 4 medica-
tions in comparison with patients with none, and other clinical outcomes showed the same
trend (P for trend < 0.05).
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Conclusions
Among ACS patients in our study, those with prior use of four preventive medications pre-
sented with less disease severity, developed less arrhythmia and had a lower risk of in-
hospital MACEs. The value of taking these medications may beyond just preventing occur-
rence of the disease.
Introduction
Acute coronary syndromes (ACS) are highly prevalent conditions, and a major contributor to
global mortality. On the basis of substantial evidence from large scale randomized trials, guide-
lines worldwide advocate the use of four preventive medications [antiplatelet agents (aspirin or
clopidogrel), angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker
(ARB), statin and beta-blockers] for ACS patients either in or after the acute phase, unless
there are contraindications.
However, while the role of these medications in prevention from the incidence of ACS and
other cardiovascular disease is well-established, for those who still developed ACS while taking
these medications it remains largely unknown if there are also benefits from use of these medi-
cations. Previous studies have had conflicting findings with respect to the association between
prior use of the four medications and subsequent clinical outcomes in patients who develop
ACS despite its use [1–10].
Further, those studies mostly used mortality as study outcomes. It remains largely unknown
that if prior use of these four medications would also impact on disease severity at presentation
and development of complications during hospitalization. In addition, none of the previous
studies examined all four medications and all in-hospital major clinical outcomes. The knowl-
edge gained in the relationship of prior use of prevention medications and in-hospital major
clinical outcomes in patients who develop ACS despite its use would help better understand
the clinical effects of these medications, and may further emphasize the importance of appro-
priate prescription of and adherence to preventive medications in relevant patients. This study
evaluated the relationship of prior use of the four preventive medications with in-hospital
major clinical outcomes in a large cohort of ACS patients in China.
Materials and Methods
Study population
The study population was drawn from the Clinical Pathways for Acute Coronary Syndromes—
Phase 2 (CPACS-2) Study [11–12]. Briefly, CPACS-2 was both a planned prospective registry
study and a cluster randomized trial that sought to provide rigorous evidence to inform the
routine use of clinical pathways in the management of ACS in China. The study recruited 75
hospitals from 17 provinces and municipalities throughout China, including 27 level 2 hospi-
tals (broadly defined as regional hospitals providing medical services to several communities)
and 48 level 3 hospitals (broadly defined as hospitals providing high level specialist medical ser-
vices to several geographic regions). Adult patients (aged> = 18 years) with a final diagnosis of
ACS were included. A total of 15,141 consecutive ACS patients were recruited between Decem-
ber 2007 and October 2010. The medical charts of eligible patients were reviewed to collect
requested information by centrally trained and certified research personnel who were not
involved with the clinical care of the patients.
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adherence to PLOS ONE policies on sharing data
and materials.
For the present analyses, patients with missing information on key variables were excluded,
including 349 patients with missing one or more outcome variables information and 2 for
missing age information. Therefore, a total of 14790 patients were included in the present
analyses.
Prior use of medications
The prior use of the four guideline-recommended medications in the study included antiplate-
let agents (aspirin or clopidogrel), ACEI/ARB, statin and beta-blockers. Prior use of preventive
medications was defined as using any of these four medications in the majority of 28 days
before onset of ACS, including those long-term users. The information on the prior use of pre-
ventive medications was collected through an interview with patients instead of from reviewing
the medical chart because the medical chart recording on this kind information in level 2 hos-
pitals in China is often lacking.
In-hospital clinical outcomes
The major in-hospital clinical outcomes in the study include: (1) ACS severity at presentation,
including type of ACS (ST-segment elevation myocardial infarction (STEMI), vs. non ST-seg-
ment elevation acute coronary syndrome (NSTE-ACS), presented with hypotension (systolic
blood pressure (SBP)<90 mmHg) or tachycardia (heart rate (HR)> = 100 beats/min). (2)
Clinical complications: major arrhythmia. (3) Major adverse cardiovascular events (MACEs):
including all-cause mortality, non-fatal new or reoccurred myocardial infarction (MI), and
non-fatal stroke. We also included major bleeding as side effect in relation to prior use of anti-
platelet medications. The detail definitions of outcomes are summarized in S1 Table.
Statistical analyses
We used logistic regression model to estimate the effect of the prior medications on clinical
outcomes. First, we built separate propensity score model for each individual drug, which is the
conditional probability of taking prior medication, based on factors from clinical judgment
and bivariate analysis, including demographic characteristics (age, sex), health insurance, his-
tory of cardiovascular disease (CVD, including MI, angina pectoris, heart failure, stroke / tran-
sient ischemic attack), risk factors of cardiovascular disease (current smoker, hypertension,
diabetes), hospital level (level 2 or level 3) [13]. Then, we calculated the adjusted odd ratios
(ORs) for each of the four medications, with the corresponding propensity score of the prior
medication in the logistic model. To test the hypothesis that the effect of prior use of preventive
medications may be mediated through the effect on disease severity at presentation, multiple
logistic regression was performed, with both disease severity and the propensity score included
as confounders.
Then, to better understand the effect of prior use of these medications alone or in combina-
tion, and at the same time coping with the significant co-linearity associations in prior use of
these medications, we classified the study population according to the number of these prior
medications and calculated ORs of the clinical outcomes for each group in comparison with
those used none of these medications. The trend of risk with increase of number of the medica-
tions was tested using the same regression model and propensity score with the number of
medications as a continuous variable. We also did the analysis separately for patients with and
without history of CVD to understand if the purpose of prior use of these medications (as for
primary or secondary prevention) modified the effects.
For the main analyses, we did not adjust for in-hospital treatment including reperfusion
(percutaneous coronary intervention, coronary artery bypass grafting, thrombolytic) and
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medications (antiplatelet agents, ACEI/ARB, statin and beta-blockers) to avoid over adjust-
ment, since it is unclear whether in-hospital treatments is administered to patients before the
non-fatal outcomes happened, or used to cope with it. However, to test the stability of our find-
ing, analyses with additional adjusted for in hospital treatments were performed as sensitivity
analyses.
For all analyses, values of P<0.05 were considered to be statistically significant. All analyses
were done using SAS version 9.3 (SAS Inc., Cary, NC, USA).
Ethical standards
Ethics approval for CPACS-2 was obtained from the Human Research Ethics Committees at
Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and
Peking Union Medical College, Beijing, China and from the University of Sydney, Australia
(Human Research Ethics Committees number: 09-2007/10276). All patients provided written
informed consent prior to their inclusion in the study.
Results
General characteristics of study population and status in prior use of
preventive medications
Table 1 detailed the baseline characteristics of all study participants by prior use of four recom-
mended medications. The study patients were predominantly male and the mean age was 64
years. Patients on prior medications were slightly older, better insured, less likely to be a cur-
rent smoker, and to receive thrombolytic therapy but significantly more likely having hyper-
tension, diabetes, and history of MI, angina pectoris, stroke/ transient ischemic attack, heart
failure, and to receive beta-blockers therapy. Among the four preventive medications, use of
antiplatelet agents was most commonly reported (31.1%), while statins were least used (13.3%).
A majority of the patients (61.7%) had no prior use of any of the four preventive medications.
Even among those with history of cardiovascular disease, the proportion of no prior use of any
of the four preventive medications was high (46.9%). (Characteristics of included and excluded
patients are provided in S2 Table.)
Prior use of four preventive medications with in-hospital clinical
outcomes
1) Association with severity of disease at presentation. Patients with prior use of any of
the four medications showed a significant lower risk of presenting with STEMI rather than
NSTE-ACS. They had significantly reduced risk of presenting with hypotension and tachycar-
dia, even after adjustment for potential confounders (Table 2).
2) Association with complications. Prior use of any of the four medications were also sig-
nificantly associated with a lower risk of developing arrhythmia during hospitalization, and the
association with arrhythmia was still significant for all four medications after adjusting for
potential confounders.
3) Association with MACEs. Prior use of any of the four medications was significantly
associated with a reduced risk of any in-hospital MACEs, death, cardiac death. The associations
were still significant after adjusting for potential confounders except for the associations
between non-fatal MI and prior use of statin, and beta-blockers.
4) Associations with MACEs and arrhythmia after further adjustment of disease severity
at presentation. After adjusting for severity of disease at presentation, many of the
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associations became non-significant. The notable exception was for prior ACEI/ARB use,
where associations remained significant (Table 3).
5) Association with severe bleeding and stroke. The ORs of developing hemorrhagic
stroke were positively associated with prior use of antiplatelet agents and the association was
still statistically significant after additional adjusting severity at presentation (Table 4).
Clinical outcomes in association with number of medications used in
combination
Our data showed significant co-linearity of the four prior medications, with Pearson coefficient
ranged from 0.3 to 0.5 (P<0.01). Thus, we analyzed the risk of clinical outcomes with the num-
ber of medications used. The risk of being presented with severity and developing arrhythmia
and MACEs during hospitalization decreased significantly as the number of prior medication
use was incrementally greater, from none to 4, even after adjusting for potential confounders
(Fig 1).
Results among patients with and without history of CVD
We observed the above associations among patients with and without the history of CVD sepa-
rately, and found that there were no significant differences except that 95% CI were generally
Table 1. Baseline characteristics of ACS patients by prior use of four recommendedmedications.
Variables Antiplatelet ACEI/ARB Statin Beta-blockers
Yes No Yes No Yes No Yes No
(N = 4601) (N = 10189) (N = 2207) (N = 12583) (N = 1973) (N = 12817) (N = 2463) (N = 12327)
Age, Mean (sd) 64.9(11.1) 63.4(12.2)* 65.4(11.0) 63.6(12.0)* 64.4(11.2) 63.8(11.9)* 64.2(11.2) 63.8(12.0)
Male 68.8 69.8 67.2 69.9* 69.5 69.5 67.2 70.0*
Health insurance 84.7 81.6* 86.0 82.0* 85.3 82.2* 84.4 82.2*
Risk factors of CVD
Current smoker 24.0 34.3* 23.2 32.5* 22.4 32.4* 22.6 32.8*
Hypertension 65.2 53.8* 84.2 52.7* 64.5 56.3* 70.9 54.7*
Diabetes 25.3 18.3* 28.7 19.0* 26.7 19.5* 25.3 19.5*
History of CVD
Myocardial infarction 25.5 6.3* 24.0 10.2* 31.2 9.3* 27.7 9.1*
Angina pectoris 62.3 31.8* 59.9 38.0* 65.6 37.6* 65.4 36.5*
Stroke/ transient ischemic attack 13.0 8.7* 13.5 9.5* 11.9 9.8* 11.1 9.9
Heart failure 10.0 4.5* 11.0 5.4* 10.8 5.5* 9.8 5.5*
Reperfusion therapy
Percutaneous coronary intervention 46.2 46.8 45.6 46.8 49.5 46.2* 47.3 46.5
Coronary artery bypass grafting 1.3 0.6* 1.0 0.8 1.1 0.8 1.6 0.7*
Thrombolytic 2.7 7.9* 2.8 6.9* 2.6 6.8* 2.4 7.1*
In-hospital medications
Antiplatelet 99.5 98.8* 99.0 99.0 99.2 99.0 99.1 99.0
ACEI/ARB 79.3 79.0 94.2 76.4* 79.5 79.0 80.4 78.8
Statin 93.8 93.8 94.3 93.7 97.9 93.2* 94.1 93.7
Beta-blockers 80.1 77.4* 82.6 77.5* 83.4 77.5* 93.1 75.3*
All data in the table are shown as %, except for age.
*P<0.05.
ACEI: angiotensin converting enzyme inhibitor; ACS: acute coronary syndrome; ARB: angiotensin receptor blocker; CVD: cardiovascular disease
doi:10.1371/journal.pone.0163068.t001
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wider (Fig 2), and the lines of trend with number of medications were fluctuant for patients
without the history of CVD (S1 Fig).
Sensitivity analyses
After additional adjusted for in-hospital treatments, ORs were calculated. The change was very
minor and had no clear evidence to reverse our conclusions (S2–S5 Figs).
Table 2. Multiple clinical outcomes (%) by prior medications use andmulti-variable adjusted ORs (95%CI) among ACS patients.
Outcome variables Antiplatelet ACEI/ARB Statin Beta-blockers
Yes No Adjusted OR a
(95%CI)
Yes No Adjusted OR a
(95%CI)
Yes No Adjusted OR a
(95%CI)
Yes No Adjusted OR a
(95%CI)
Severity at
presentation
STEMI subtype b 23.8 46.6 0.50(0.46–0.54) 23.3 42.4 0.58(0.52–0.65) 20.3 42.5 0.47(0.42–0.53) 19.2 43.6 0.43(0.39–0.48)
SBP<90mmHg 1.0 2.2 0.53(0.38–0.75) 0.8 2.0 0.48(0.29–0.80) 0.8 2.0 0.49(0.29–0.83) 0.7 2.0 0.40(0.24–0.67)
HR> = 100bpm 6.5 9.4 0.69(0.60–0.80) 7.2 8.8 0.82(0.68–0.98) 5.0 9.1 0.56(0.45–0.69) 5.7 9.1 0.67(0.55–0.80)
Complications
Arrhythmia 4.4 6.5 0.63(0.53–0.75) 4.0 6.2 0.64(0.50–0.80) 3.4 6.2 0.53(0.40–0.68) 3.0 6.4 0.45(0.35–0.58)
MACE
Total MACEs 3.9 5.4 0.70(0.58–0.84) 3.4 5.2 0.59(0.46–0.76) 3.7 5.2 0.73(0.57–0.94) 3.5 5.3 0.70(0.55–0.89)
Death 2.1 3.4 0.62(0.49–0.79) 1.8 3.2 0.55(0.39–0.77) 1.6 3.2 0.52(0.36–0.76) 1.8 3.3 0.63(0.46–0.87)
Cardiac
death
1.8 3.2 0.57(0.44–0.73) 1.5 3.0 0.48(0.33–0.70) 1.3 3.0 0.43(0.29–0.66) 1.6 3.0 0.58(0.41–0.82)
Non-fatal MI 1.1 1.6 0.64(0.45–0.90) 0.7 1.6 0.42(0.25–0.71) 1.3 1.4 0.91(0.59–1.40) 1.0 1.5 0.67(0.43–1.04)
a Adjusted OR: adjusting for age, sex, insurance, history of CVD (myocardial infarction, angina pectoris, heart failure, stroke/ transient ischemic attack), risk
factors of CVD (current smoker, hypertension, diabetes), and level of hospital.
b STEMI compared to NSTE-ACS.
ACEI: angiotensin converting enzyme inhibitor; ACS: acute coronary syndrome; ARB: angiotensin receptor blocker; CI: confidence interval; CVD:
cardiovascular disease; HR: heart rate; MACEs: major adverse cardiovascular events; MI: myocardial infarction; OR: odd ratio; SBP: systolic blood
pressure; STEMI: ST-segment elevation myocardial infarction; NSTE-ACS: non ST-segment elevation acute coronary syndrome;
doi:10.1371/journal.pone.0163068.t002
Table 3. ORs (95%CI) of prior medications use on in-hospital development of complications and MACEs among ACS patients after further adjust-
ing for severity at presentation.
Outcome variables Antiplatelet ACEI/ARB Statin Beta-blockers
Complications
Arrhythmia 0.84(0.71–1.01) 0.80(0.63–1.01) 0.73(0.56–0.96) 0.65(0.50–0.84)
Total MACEs
MACEs 0.92(0.76–1.11) 0.72(0.56–0.94) 1.05(0.80–1.36) 1.01(0.79–1.30)
Death 0.82(0.64–1.05) 0.68(0.48–0.96) 0.77(0.52–1.13) 0.95(0.68–1.33)
Cardiac death 0.75(0.58–0.98) 0.60(0.41–0.88) 0.63(0.41–0.97) 0.89(0.63–1.27)
Non-fatal MI 0.88(0.62–1.25) 0.54(0.32–0.91) 1.36(0.87–2.11) 1.01(0.65–1.58)
All ORs were adjusting for age, sex, insurance, history of CVD (myocardial infarction, angina pectoris, heart failure, stroke / transient ischemic attack), risk
factors of CVD (current smoker, hypertension, diabetes), hospital level plus severity at presentation (ACS subtype, SBP <90mmHg, HR> = 100bpm).
ACEI: angiotensin converting enzyme inhibitor; ACS: acute coronary syndrome; ARB: angiotensin receptor blocker; CI: confidence interval; CVD:
cardiovascular disease; HR: heart rate; MACEs: major adverse cardiovascular events; MI: myocardial infarction; OR: odd ratio; SBP: systolic blood
pressure;
doi:10.1371/journal.pone.0163068.t003
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Discussion
This large observational study of 14790 ACS patients showed that their prior use of antiplatelet
agents, ACEI/ARB, statin and beta-blockers were significantly associated with lower severity
of presenting ACS, a lower risk of developing in-hospital complications, including serious
arrhythmia, major cardiovascular events and death. Beneficial impact of four prior medications
on severity and complication was observed in patients with CVD history and patients without
CVD history. Prior antiplatelet use was associated with greater risk of hemorrhagic stroke.
With higher numbers of prior medication use, the risk of presenting with severity and develop-
ing arrhythmia and MACEs became significantly lower. And we found no differences in these
associations between patients with and without history of CVD. These findings suggest that the
benefits of these medications may extend beyond the known effect in prevention of occurrence
of ACS, but may reduce the severity of disease and reduce in-hospital adverse outcomes in
those who do develop an ACS anyway despite their prior use.
Our findings on the effects of antiplatelet agents were in concordance with GRACE (2002)
and Medicare. In GRACE study, prior use of aspirin was not only associated with less likely to
present with STEMI, but also reduced the incidence of in-hospital death significantly. In Medi-
care study, prior aspirin use lowered in-hospital and 6 month mortality [1–2]. In contrast, the
TIMI, ESSENCE, PRISM-PLUS and PURSUIT studies suggested prior aspirin use did not yield
benefit, and might slightly increase the incidence of death, recurrent ischemic events or emer-
gency reperfusion therapy [3–6]. Several reasons could help to explain different findings. First,
these studies were all clinical trials and the study participants were highly selected and very dif-
ferent from the patients in real world practice, such as study participants in our study and
those from GRACE and Medicare. Second, the study aims of TIMI, ESSENCE, PRISM-PLUS
and PURSUIT were to estimate effect of anticoagulants, though prior use of antiplatelet agents
were neither listed in the exclusion criteria nor were wash-out periods required. Use of antico-
agulant or fibrinolytic medications in the trials would greatly increase the risk of bleeding
among patients with prior antiplatelet agent use, likely leading to significantly higher risks of
hemorrhagic stroke or death. In these studies, the in-hospital rate of hemorrhagic stroke and
other major bleeding were high, for example with 8.3% of patients without prior antiplatelet
use experiencing moderate or severe bleeding in the PURSUIT trial. In fact, prior use of anti-
platelet agents was significantly associated with in-hospital hemorrhagic stroke with a nearly
three-fold higher risk in our study. But, because hemorrhagic stroke was a composition of
MACEs, it could not change the conclusion on MACEs. In addition, the proportion of prior
aspirin use was very high in TIMI-IIB, ESSENCE, PRISM-PLUS and PURSUIT, ranging from
59% in PRISM-PLUS study to 84% in TIMI-IIB study.
Table 4. Bleeding (%) by prior antiplatelet agents use andmulti-variable adjusted ORs (95%CI) among ACS patients (%).
Bleeding events Prior use of antiplatelet, % Adjusted OR a (95%CI) Adjusted OR b (95%CI)
Yes (N = 4601) No (N = 10189)
Major bleeding 2.0 1.5 1.33(1.00–1.77) 1.55(1.16–2.07)
Hemorrhagic stroke 0.6 0.2 2.96(1.56–5.62) 2.97(1.54–5.70)
Other bleedings 1.4 1.3 1.09(0.79–1.50) 1.31(0.94–1.82)
a adjusting for age, sex, insurance, history of CVD (myocardial infarction, angina pectoris, heart failure, stroke/ transient ischemic attack), risk factors of CVD
(current smoker, hypertension, diabetes), and level of hospital.
b adjusting for age, sex, insurance, history of CVD (myocardial infarction, angina pectoris, heart failure, stroke / transient ischemic attack), risk factors of CVD
(current smoker, hypertension, diabetes), level of hospital plus severity at presentation (ACS subtype, SBP <90mmHg, HR> = 100bpm).
ACS: acute coronary syndrome; CI: confidence interval; CVD: cardiovascular disease; HR: heart rate; OR: odd ratio; SBP: systolic blood pressure;
doi:10.1371/journal.pone.0163068.t004
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Few studies have reported the association of the prior use of other three medications with
risk of developing clinical outcomes among ACS patients. GRACE (2004 and 2009) study found
that prior statin use was associated with less diagnosis of acute MI among ACS patients, and
lower incidence of in-hospital complications (congestive heart failure and severe arrhythmia),
death, and MI recurrence [7–8]. Herlitz reported no significant correlation between prior beta-
blockers and acute MI recurrence, death within 28 days among patients with suspected acute
MI [9]. Singh demonstrated that the prior ACEI had no significant association with in-hospital
death andMI [10]. Our study generally confirmed the findings from some previous studies but
added new knowledge on the association with severity of disease at presentation and develop-
ment of arrhythmia in hospital, and we adjusted more fully for possible confounders.
Fig 1. Trends in risk of multiple in-hospital clinical outcomes with increasing number of prior
medications used.HR: heart rate; MACEs: major adverse cardiovascular events; OR: odd ratio; SBP:
systolic blood pressure; STEMI: ST-segment elevation myocardial infarction;
doi:10.1371/journal.pone.0163068.g001
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Unlike previous studies, we included all four preventive medications and observed the asso-
ciation of the risk of clinical outcomes with the number of medications used, rather than put-
ting them into one model to adjust for their confounding effect for each other. Because they are
often used together, and our data show significant co-linearity. Our finding that the number of
medications showed a ‘dose-response’ relationship with the risk of adverse clinical outcomes
suggests that all these four medications may have an effect in reducing the severity of the pre-
senting ACS, and well as the risk of subsequent complications and early mortality.
To understand whether the effects observed on in-hospital events might be mediated by the
severity of the presenting ACS, we further adjusted for the disease severity in the models to fit
the association with these clinical endpoints. The results showed that all ORs approached closer
to 1.0 and the associations of prior use of antiplatelet agents, statin and beta-blockers with
MACEs became no longer significant. These findings suggest the beneficial effects of prior use
of these medications may be mainly mediated through increasing the likelihood of developing
a less severe ACS when this does occur. However, other mechanisms might be important in
terms of prior statin, beta-blockers use and risk of arrhythmia, and the effects of prior ACEI/
ARB more broadly. Although some studies also reveal patients on prior medication were more
likely to present with UA as opposed to AMI, the mechanism is still unclear [14–15].
The interpretation of our results required caution due to the following limitations. First, this
is an observational study and we cannot account for unmeasured and unknown confounders.
Second, we excluded 351 patients from the study because of missing data on key variables.
However, with multiple imputations, we found almost the same results (data not shown).
Third, similar weight was given to all medications when looking at the combined effects. How-
ever, the benefits of each medications are all positive with similar OR values. Fourth, only ACS
patients included may raises concerns of selection bias. However, the focus of our study is to
reveal the effect of prior medications in patients developing an ACS anyway despite their prior
use, not the effect to avert an ACS. As such, we believe that our work provides the best available
assessment of the effects of prior medications use on the in-hospital course of ACS.
Conclusions
In summary, among ACS patients in our study, those with prior use of four preventive medica-
tions presented with less disease severity, developed less arrhythmia and had a lower risk of in-
hospital MACEs. The beneficial effect of prior use of these medications may be mainly medi-
ated through increasing the likelihood of developing ACS with less severity even if it does
Fig 2. ORs (95%CI) of prior medications on in-hospital clinical outcomes among ACS patients,
stratified by history of CVD. ACEI: angiotensin converting enzyme inhibitor; ACS: acute coronary
syndrome; ARB: angiotensin receptor blocker; CI: confidence interval; CVD: cardiovascular disease; HR:
heart rate; MACEs: major adverse cardiovascular events; OR: odd ratio; SBP: systolic blood pressure;
STEMI: ST-segment elevation myocardial infarction;
doi:10.1371/journal.pone.0163068.g002
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occur. The findings indicated that these medications may have benefits beyond the prevention
of occurrence of disease.
Supporting Information
S1 Fig. Trends in risk of multiple in-hospital clinical outcomes with increasing number of
prior medications used, stratified by history of CVD. CVD: cardiovascular disease; HR:
heart rate; MACEs: major adverse cardiovascular events; OR: odd ratio; SBP: systolic blood
pressure; STEMI: ST-segment elevation myocardial infarction.
(TIF)
S2 Fig. Multi-variable adjusted ORs of prior antiplatelet on arrhythmia and MACEs. The
top part shows ORs in Table 2; the bottom part shows ORs with additional adjusted for in-hos-
pital treatment including reperfusion therapy (thrombolytic therapy, percutaneous coronary
intervention, coronary artery bypass grafting) and medications (antiplatelet agents, ACEI/
ARB, beta-blockers, statin). ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin
receptor blocker; MACEs: major adverse cardiovascular events; MI: myocardial infarction; OR:
odd ratio.
(TIF)
S3 Fig. Multi-variable adjusted ORs of prior ACEI/ARB on arrhythmia and MACEs. The
top part shows ORs in Table 2; the bottom part shows ORs with additional adjusted for in-hos-
pital treatment including reperfusion therapy (thrombolytic therapy, percutaneous coronary
intervention, coronary artery bypass grafting) and medications (antiplatelet agents, ACEI/
ARB, beta-blockers, statin). ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin
receptor blocker; MACEs: major adverse cardiovascular events; MI: myocardial infarction; OR:
odd ratio.
(TIF)
S4 Fig. Multi-variable adjusted ORs of prior statin on arrhythmia and MACEs. The top
part shows ORs in Table 2; the bottom part shows ORs with additional adjusted for in-hospital
treatment including reperfusion therapy (thrombolytic therapy, percutaneous coronary inter-
vention, coronary artery bypass grafting) and medications (antiplatelet agents, ACEI/ARB,
beta-blockers, statin). ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin recep-
tor blocker; MACEs: major adverse cardiovascular events; MI: myocardial infarction; OR: odd
ratio.
(TIF)
S5 Fig. Multi-variable adjusted ORs of prior beta-blockers on arrhythmia and MACEs. The
top part shows ORs in Table 2; the bottom part shows ORs with additional adjusted for in-hos-
pital treatment including reperfusion therapy (thrombolytic therapy, percutaneous coronary
intervention, coronary artery bypass grafting) and medications (antiplatelet agents, ACEI/
ARB, beta-blockers, statin). ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin
receptor blocker; MACEs: major adverse cardiovascular events; MI: myocardial infarction; OR:
odd ratio.
(TIF)
S1 Table. Detail definitions of outcomes.
(DOCX)
S2 Table. Baseline characteristics of included and excluded ACS patients.
(DOCX)
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